In Baudin et al’s (39) study, circulating CgA and NSE were measured in patients with neuroendocrine tumors (NET) and non-NET patients, and an analysis comparing them concluded that CgA appeared to be more reflective of tumor progression than NSE, suggesting that CgA should be used as a marker for screening patients with NET. Here, ENO2 is linked to neuroendocrine neoplasm.